Sheraton Seattle Hotel Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2017



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics (A9)


Organizer(s) Johnathan R. Whetstine, Jessica K. Tyler and Rab K. Prinjha
January 29—February 2, 2017
Sheraton Seattle Hotel • Seattle, Washington USA
Discounted Abstract Deadline: Sep 29, 2016
Abstract Deadline: Oct 27, 2016
Scholarship Deadline: Sep 29, 2016
Discounted Registration Deadline: Nov 30, 2016

Sponsored by Incyte Corporation, Merck & Co., Inc., Taylor & Francis and Vertex Pharmaceuticals Incorporated

Summary of Meeting:
Epigenetics impacts human health and disease. Data from a range of diseases (cancer, neurological and immunological disorders) have documented mutations, altered expression and copy number alterations in numerous epigenetic factors (histones, DNA and chromatin modifying enzymes, reader proteins, chromatin modulators and noncoding RNAs). Genome-wide data has also illustrated the relationship between altered epigenetic states (e.g., modified DNA and histones) and disease onset and progression. Therefore, there is a need to discover the molecular mechanisms and interplay between epigenetic regulators. These mechanistic insights will shed light on the impact epigenetic regulators have on cellular homeostasis, while resolving their pathogenic contribution to disease states. This meeting is aimed at interrogating the most current knowledge surrounding the epigenetic events modulating nuclear function (gene expression regulation, enhancer modulation, domains and structural organization as well as cell division and differentiation), while relating this to developmental and disease models. In addition, this meeting will highlight the impact that preclinical and clinical epigenetic therapeutics have on a panel of diseases including cancer and neurological disorders. By presenting these various aspects associated with epigenetics and diverse disease, this unique forum should promote dynamic discussions, interactions and collaborations that will impact our understanding of disease and possible treatment strategies. Opportunities for trainee career development, networking and oral presentations are provided by a “Focus on Junior Scientists” session, a panel discussion and mixer with scientific editors and another with industry scientists.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Sunday, January 29 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 2 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 3 in order to fully experience the meeting.

SUNDAY, JANUARY 29

4:00—8:00 PM
Arrival and Registration

Grand Ballroom Foyer
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Grand Ballroom Foyer

MONDAY, JANUARY 30

7:30—8:30 AM
Breakfast

Grand Ballroom AB
8:30—9:30 AM
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Grand Ballroom CD
* Johnathan R. Whetstine, Massachusetts General Hospital, USA

* Jessica K. Tyler, Weill Cornell Medicine, USA

* Rab K. Prinjha, GlaxoSmithKline, UK

Rudolf Jaenisch, Whitehead Institute for Biomedical Research, USA
Epigenetics, Stem Cells and Disease Research

9:30—11:45 AM
Epigenetics and Genome Organization
Meeting has ended...abstracts no longer viewable online.

Grand Ballroom CD
* Bradley E. Bernstein, Massachusetts General Hospital, USA

Thomas Misteli, NCI, National Institutes of Health, USA
Deep Imaging of the Genome

Coffee Break

Bas van Steensel, Netherlands Cancer Institute, Netherlands
Architecture, Dynamics and Function of Genome - Nuclear Lamina Interactions

Kadir Akdemir, MD Anderson Cancer Center, USA
Short Talk: Spatial Organization of the Genome & Structural Alterations in Human Cancers

Robert Hansel-Hertsch, University of Cambridge, UK
Short Talk: G-Quadruplex Structures Mark Human Regulatory Chromatin

Janneke Peeters, University Medical Center Utrecht, Netherlands
Short Talk: Enhancers in Autoimmune Disease Cells Contribute to Disease Pathogenesis and Can be Targeted to Reduce Autoimmunity

11:45 AM—5:00 PM
On Own for Lunch

11:45 AM—1:00 PM
Poster Setup

Grand Ballroom AB
1:00—10:00 PM
Poster Viewing

Grand Ballroom AB
4:30—5:00 PM
Coffee Available

Grand Ballroom Foyer
5:00—7:00 PM
From Epigenomics to Disease
Meeting has ended...abstracts no longer viewable online.

Grand Ballroom CD
* Henk G. Stunnenberg, Radboud University, Netherlands

Bradley E. Bernstein, Massachusetts General Hospital, USA
Epigenetic Mechanisms of Tumor Initiation and Evolution

Joseph F. Costello, University of California, San Francisco, USA
Losing Driver Mutations, Gaining Insight into Epigenome Evolution

John A. Stamatoyannopoulos, University of Washington, USA
A Roadmap to the Living Genome

Daniel S. Day, Whitehead Institute, USA
Short Talk: Tumor Progression through Sequential Disruption of Insulated Neighborhoods

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Grand Ballroom AB
7:30—10:00 PM
Poster Session 1

Grand Ballroom AB

TUESDAY, JANUARY 31

7:30—8:30 AM
Breakfast

Grand Ballroom AB
8:30—11:45 AM
Epigenetic Modification Dynamics: Gateway to Understanding Disease
Meeting has ended...abstracts no longer viewable online.

Grand Ballroom CD
* Jessica K. Tyler, Weill Cornell Medicine, USA

Henk G. Stunnenberg, Radboud University, Netherlands
Epigenomics Uncovers Dysregulated Regulatory Pathways

Shelley L. Berger, University of Pennsylvania, USA
Histone Acetylation Pathways in Learning and Memory

Coffee Break

Anne Schaefer, Mount Sinai School of Medicine, USA
Polycomb Repressive Complex 2 (PRC2) Silences Genes Responsible for Neurodegeneration

Robert E. Kingston, Massachusetts General Hospital, USA
Nucleosome Compaction as a Regulatory Mechanism during Development

Panagiotis Ntziachristos, Northwestern University, USA
Short Talk: Targeting Deubiquitination in Acute Leukemia

Woojin An, University of Southern California, USA
Short Talk: MacroH2A Suppresses Prostate Cancer Bone Metastasis through Cooperation with HP1 and H1.2

11:45 AM—5:00 PM
On Own for Lunch

11:45 AM—1:00 PM
Poster Setup

Grand Ballroom AB
1:00—10:00 PM
Poster Viewing

Grand Ballroom AB
4:30—5:00 PM
Coffee Available

Grand Ballroom Foyer
5:00—7:00 PM
Chromatin Modifiers, Development and Disease
Meeting has ended...abstracts no longer viewable online.

Grand Ballroom CD
* Anne Schaefer, Mount Sinai School of Medicine, USA

Jessica K. Tyler, Weill Cornell Medicine, USA
Chromatin Assembly and Disassembly

Johnathan R. Whetstine, Massachusetts General Hospital, USA
Epigenetic Mechanisms Impact Cell Cycle and Somatic DNA Copy Number

Peter W. Lewis, University of Wisconsin-Madison, USA
Short Talk: H3 K36M Oncohistone Promotes Sarcomagenesis through Altered Methylation Landscape

David M. Truong, New York University Langone Medical Center, USA
Short Talk: Resetting the Yeast Epigenome with Human Nucleosomes

Kimberly J. Cocce, Duke University, USA
Short Talk: Genome Wide Profiling Identifies a FoxA1/GRHL2 Interaction that Functions as a Mediator of Endocrine Therapy Resistance in a Model of Luminal Breast Cancer

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Grand Ballroom AB
7:30—10:00 PM
Poster Session 2

Grand Ballroom AB

WEDNESDAY, FEBRUARY 1

7:30—8:30 AM
Breakfast

Grand Ballroom AB
8:00—8:30 AM
Poster Setup

Grand Ballroom AB
8:30 AM—5:00 PM
Poster Viewing

Grand Ballroom AB
8:30—11:45 AM
Epigenetics and Cell States
Meeting has ended...abstracts no longer viewable online.

Grand Ballroom CD
* François Fuks, Université Libre De Bruxelles, Belgium

Emily Bernstein, Mount Sinai School of Medicine, USA
Epigenetic Sensitivities in Cancer

Luciano Di Croce, Centre for Genomic Regulation, Spain
Unveiling Polycomb Functions in Stem Cells and Cancer

Coffee Break

Maria-Elena Torres-Padilla, Helmholtz Centre Munich, Germany
Epigenetic Mechanisms in Early Mammalian Development

Gerald R. Crabtree, Stanford University, USA
Chromatin Remodeling: Insights from the Genetics of Human Disease and New Methods

Elizabeth Heller, University of Pennsylvania, USA
Short Talk: Targeted Neuroepigenetic Editing of Cdk5 Regulates Behavior

Ana Patricia Gomes, Weill Cornell Medicine, USA
Short Talk: The CAF1 Complex Promotes Tumor Progression through Re-Distribution of Histone H3.3 in the Chromatin

11:45 AM—12:30 PM
Lunch

Grand Ballroom AB
12:00—2:30 PM
Poster Session 3

Grand Ballroom AB
2:30—4:30 PM
Workshop: Breakthroughs in Technology and Disease

Grand Ballroom CD
* Cheryl Arrowsmith, University of Toronto, Canada

Hatice Efsun Arda, Stanford University, USA
Lineage Specific Regulomes of the Human Pancreas

Manfred Jung, University of Freiburg, Germany
Chemical Tools for Methyl Lysine Readers

Victoria Le, The Salk Institute of Biological Studies, USA
Finding Translocations in Cancer Genomes using Chromatin Interaction Data

Tonya Marie Gilbert, Massachusetts General Hospital, USA
In vivo HDAC Imaging in Schizophrenia using Combined MR-PET

Ari Allyn-Feuer, University of Michigan Medical School, USA
The Pharmacogenomics Informatics Pipeline: An Integrative Multi-Omics Platform for Variant Discovery

Nabieh Ayoub, Technion University, Israel
Characterizing the Biological Functions of KDM4A-D Interactions with RNA Molecules

Shinya Oki, Kyushu University, Japan
The Transcription Factor Landscape Decodes the Enhancers and Risk Variants in Non-Coding Regions

Yael David, Memorial Sloan Kettering Cancer Center, USA
Towards Synthetic Chromatin: Modifying Histones In Live Cells Using Protein Trans-Splicing

4:30—5:00 PM
Coffee Available

Grand Ballroom Foyer
5:00—7:15 PM
Epigenetic States and RNA
Meeting has ended...abstracts no longer viewable online.

Grand Ballroom CD
* Emily Bernstein, Mount Sinai School of Medicine, USA

Tony Kouzarides, University of Cambridge, UK
Modifications of RNA: Their Function and Role in Cancer

Ramin Shiekhattar, University of Miami, USA
Targeting Integrator in Cancer

Ali Shilatifard, Northwestern University, USA
Principles of Epigenetics and Chromatin in Development and Human Disease

François Fuks, Université Libre De Bruxelles, Belgium
Short Talk: Transcriptome-Wide Distribution and Function of RNA Hydroxymethylcytosine

Guillermo Barreto, Max Planck Institute for Heart and Lung Research, Germany
Short Talk: Nuclear miRNA/exosome-Mediated Transcriptional Silencing within the Context of TGFB1 Signaling and Idiopathic Pulmonary Fibrosis

7:15 PM
On Own for Dinner


THURSDAY, FEBRUARY 2

7:30—8:30 AM
Breakfast

Grand Ballroom AB
8:30—11:45 AM
Targeting Epigenetics
Meeting has ended...abstracts no longer viewable online.

Grand Ballroom CD
* Johnathan R. Whetstine, Massachusetts General Hospital, USA

Rab K. Prinjha, GlaxoSmithKline, UK
Clinical Progression of BET Inhibitors

Cheryl Arrowsmith, University of Toronto, Canada
Probing the Epigenome for New Therapeutic Opportunities

Coffee Break

Alexander Tarakhovsky, Rockefeller University, USA
Uncovering Histone Mimics and Disease

Jesse J. Smith, Epizyme, USA
The EZH2 Inhibitor Tazemetostat as a Potential Therapeutic for Non-Hodgkin Lymphoma and Genetically Defined Solid Tumors

Norm Wong, Resverlogix Corporation, Canada
Short Talk: Selective BET Inhibitors are Useful for Normalizing Inflammation Leading to Reduced Cardiovascular Disease (CVD) in Humans and in an Animal Model of Rheumatoid Arthritis

Shaokun Shu, Dana-Farber Cancer Institute, USA
Short Talk: Response and Resistance to BET Bromodomain Inhibitors in Triple Negative Breast Cancer

11:45 AM—5:00 PM
On Own for Lunch

4:30—5:00 PM
Coffee Available

Grand Ballroom Foyer
5:00—6:45 PM
Epigenetics and Therapy
Meeting has ended...abstracts no longer viewable online.

Grand Ballroom CD
* Rab K. Prinjha, GlaxoSmithKline, UK

Tamara Maes, Oryzon Genomics, Spain
Development of Lysine-Specific Demethylase Inhibitors for Oncological and Neurodegenerative Disease

Erica Korb, Rockefeller University, USA
Short Talk: Treatment of Fragile X Syndrome with the BET Inhibitor Jq1

Dineo Khabele, Vanderbilt University, USA
Novel Epigenetic Drug Regimens to Enhance PARP Inhibitor Efficacy in Ovarian Cancer

6:45—7:00 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Grand Ballroom CD
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Grand Ballroom AB
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Grand Ballroom AB

FRIDAY, FEBRUARY 3

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Incyte Corporation Merck & Co., Inc.
Taylor & Francis Vertex Pharmaceuticals Incorporated

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

March of Dimes Foundation, Grant No. 4-FY16-317 Porvair Sciences Ltd & Chromatrap
Zymo Research Corporation
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Epizyme, Inc.


GlaxoSmithKline UK


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676